Patents by Inventor Jean-Francois Delhomel

Jean-Francois Delhomel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYMORPHS OF ELAFIBRANOR
    Publication number: 20230094109
    Abstract: The present invention relates to novel crystalline forms of elafibranor.
    Type: Application
    Filed: February 4, 2021
    Publication date: March 30, 2023
    Inventors: Karine BERTRAND, Jean-François DELHOMEL, Alice ROUDOT
  • PHOSPHATE DERIVATIVES OF RORGAMMA MODULATORS AND USES THEREOF
    Publication number: 20230039185
    Abstract: The present invention relates to phosphate derivatives of formula (I), and their therapeutic uses, preferably for treating a respiratory disease. The present invention further relates to pharmaceutical compositions and devices comprising such compounds.
    Type: Application
    Filed: December 17, 2020
    Publication date: February 9, 2023
    Inventors: JEAN-FRANÇOIS DELHOMEL, ROBERT WALCZAK, PEGGY PARROCHE, ANNE-MARIE SAVERET
  • RORGAMMA MODULATORS AND USES THEREOF
    Publication number: 20220133716
    Abstract: The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Application
    Filed: October 5, 2021
    Publication date: May 5, 2022
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • RORgamma modulators and uses thereof
    Patent number: 11160801
    Abstract: The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 2, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • Rorgamma modulators and uses thereof
    Patent number: 11077115
    Abstract: The present invention provides novel compounds of formula (Ia) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: August 3, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases
    Patent number: 11052092
    Abstract: The present invention provides e.g. N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating e.g. autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases or cholestatic diseases, such as e.g. arthitis and asthma.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: July 6, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak
  • RORgamma modulators and uses thereof
    Patent number: 10987351
    Abstract: The present invention provides novel compounds of formula (Ia) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: April 27, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
    Patent number: 10799510
    Abstract: The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: October 13, 2020
    Assignee: Genfit
    Inventors: Maryline Bourotte, Jean-Francois Delhomel, Mathieu Dubernet, Marie-Helene Gouy
  • RORGAMMA MODULATORS AND USES THEREOF
    Publication number: 20200000815
    Abstract: The present invention provides novel compounds of formula (Ia) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Application
    Filed: January 29, 2018
    Publication date: January 2, 2020
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • RORGAMMA MODULATORS AND USES THEREOF
    Publication number: 20190388414
    Abstract: The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Application
    Filed: January 29, 2018
    Publication date: December 26, 2019
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXA ZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES
    Publication number: 20190365768
    Abstract: The present invention provides e.g. N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating e.g. autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases or cholestatic diseases, such as e.g. arthitis and asthma.
    Type: Application
    Filed: January 29, 2018
    Publication date: December 5, 2019
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak
  • RORGAMMA MODULATORS AND USES THEREOF
    Publication number: 20190358223
    Abstract: The present invention provides novel compounds of formula (Ia) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Application
    Filed: January 29, 2018
    Publication date: November 28, 2019
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • Heterocyclic derivatives as RORgamma modulators
    Patent number: 9902725
    Abstract: The present invention provides novel compounds of formula (I) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: February 27, 2018
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Robert Walczak, Zouher Majd, Emilie Pihan, Pascal Bonnet, Enrico Perspicace
  • HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS
    Publication number: 20170349582
    Abstract: The present invention provides novel compounds of formula (I) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, fibrotic diseases, or cholestatic diseases.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 7, 2017
    Applicant: GENFIT
    Inventors: Jean-Francois Delhomel, Robert Walczak, Zouher Majd, Emilie Pihan, Pascal Bonnet, Enrico Perspicace
  • DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS
    Publication number: 20170296548
    Abstract: The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
    Type: Application
    Filed: March 6, 2017
    Publication date: October 19, 2017
    Inventors: Maryline Bourotte, Jean-Francois Delhomel, Mathieu Dubernet, Marie-Helene Gouy
  • Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
    Patent number: 9586963
    Abstract: The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: March 7, 2017
    Assignee: Genfit
    Inventors: Maryline Bourotte, Jean-Francois Delhomel, Mathieu Dubernet, Marie-Helene Gouy
  • 1,3-diphenylpropane derivatives, preparations and uses thereof
    Patent number: 9115073
    Abstract: The present invention relates to novel 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising the same and therapeutic uses thereof, in particular in the fields of human and animal health. The compounds according to the present invention have intrinsic PPAR agonist properties. They are therefore of particular interest in the treatment of metabolic and/or inflammatory diseases and particularly peripheral and central diseases associated with the metabolic syndrome, such as diverse forms of steatohepatitis, type 2 diabetes, diverse neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and multiple sclerosis.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: August 25, 2015
    Assignee: GENFIT
    Inventors: Mathieu Dubernet, Jean-Francois Delhomel, Karine Bertrand
  • DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS
    Publication number: 20150038503
    Abstract: The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
    Type: Application
    Filed: September 27, 2012
    Publication date: February 5, 2015
    Applicant: GENFIT
    Inventors: Maryline Bourotte, Jean-Francois Delhomel, Mathieu Dubernet, Marie-Helene Gouy
  • 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF
    Publication number: 20140350112
    Abstract: The present invention relates to novel 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising the same and therapeutic uses thereof, in particular in the fields of human and animal health. The compounds according to the present invention have intrinsic PPAR agonist properties. They are therefore of particular interest in the treatment of metabolic and/or inflammatory diseases and particularly peripheral and central diseases associated with the metabolic syndrome, such as diverse forms of steatohepatitis, type 2 diabetes, diverse neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and multiple sclerosis.
    Type: Application
    Filed: December 28, 2012
    Publication date: November 27, 2014
    Applicant: GENFIT
    Inventors: Mathieu Dubernet, Jean-Francois Delhomel, Karine Bertrand
  • Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof
    Patent number: 8258182
    Abstract: The present invention involves substituted 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising them and the therapeutic uses thereof, in particular in the fields of human and animal health.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: September 4, 2012
    Assignee: Genfit
    Inventors: Jean-François Delhomel, Rémy Hanf, Karine Caumont-Bertrand